Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.47 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.47 |
| ▸ | ALDH1A3 | P47895 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1133951 | 0.98 | TRIM24 (0.48) | ALDH1A1SMN1; SMN2KDM4ETRIM24TRIM33 | |
| SCHEMBL25308181 | 0.94 | TRIM24 (0.44) | ALDH1A1SMN1; SMN2KDM4ETRIM24TRIM33 | |
| SCHEMBL1133918 | 0.81 | POLB (0.57) | ALDH1A1KDM4EALDH1A3POLBHDAC6 | |
| SCHEMBL16755649 | 0.81 | ALDH1A1 (0.53) | ALDH1A1KDM4EHDAC6MAPTTSHR | |
| SCHEMBL16654217 | 0.81 | TAAR1 (0.57) | ALDH1A1SMN1; SMN2KDM4EHDAC6TSHR | |
| Hydrochloric Acid SCHEMBL28861662 | 0.79 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2KDM4EHDAC6TSHR | |
| SCHEMBL25197619 | 0.78 | AOC3 (0.42) | KDM4EPOLBHDAC6 | |
| SCHEMBL15166116 | 0.78 | KDM4E (0.37) | ALDH1A1SMN1; SMN2KDM4ETRIM24TRIM33 | |
| SCHEMBL17832213 | 0.77 | OGA (0.43) | HDAC6 | |
| SCHEMBL29631848 | 0.77 | POLB (0.41) | ALDH1A1KDM4EPOLBHDAC6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102884062-B | Aminopyrimidine inhibitors of kinases | 嘉世高制药公司 | 2016-08-03 | — | — | CN | disclosed |
| US-9157077-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2516425-B1 | AMINOPYRIMIDINE KINASE INHIBITORS | JASCO PHARMACEUTICALS LLC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-20140080799-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2014-03-20 | — | — | US | disclosed |
| CN-102066360-B | Quinoline-or isoquinoline-substituted P2X7 antagonists | JANSSEN PHARMACEUTICA NV | 2013-10-30 | — | — | CN | disclosed |
| US-8563539-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2013-10-22 | — | — | US | disclosed |
| US-8431704-B2 | Quinoline or isoquinoline substituted P2X7 antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-30 | — | — | US | disclosed |
| CN-102884062-A | Aminopyrimidine kinase inhibitors | JASCO PHARMACEUTICALS LLC | 2013-01-16 | — | — | CN | disclosed |
| EP-2516425-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals LLC (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2285800-B1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-16 | — | — | EP | disclosed |
| EP-2091917-A1 | ION CHANNEL MODULATORS | Wyeth a Corporation of the State of Delaware (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008073936-A1 | CARBOXAMIDE DERIVATIVES AS ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073936-A1 | CARBOXAMIDE DERIVATIVES AS ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073929-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073461-A2 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073461-A2 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073934-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073934-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073929-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-1993006118-A1 | ANTIBACTERIAL, ANTIMYCOPLASMAL COMPOUNDS RELATED TO MUPIROCIN | SMITHKLINE BEECHAM PLC (GB) | 1993-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080799-A1 | Aminopyrimidine Kinase Inhibitors | PIM1, PIM2, PIM3 | ALDH1A1 3604/4885SMN1; SMN2 3555/4885KDM4E 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.